Volume Alert - MACK 9.27 Merrimack Pharmaceuticals Inc $MACK Hit a high today of 9.34 Closing the day 10:30 at 9.27 +0.33 +3.69% With a day low of 9.05 and a total volume of 895,523.
MACK Recent Posts: http://investorshangout.com/Merrimack-Pharmac...ACK-90045/
MACK Merrimack Pharmaceuticals Inc Recent Headline News
Insider Trading Alert - MACK, GWRE And CCOI Traded By Insiders
at The Street - 2 hrs 21 mins ago
Stocks with insider trader activity include MACK, GWRE and CCOI
MACK: 8.73 (-0.21), GWRE: 49.41 (-0.67), CCOI: 34.83 (-0.32)
Merrimack cancer drug candidate Fast Track'd
Seeking Alpha - at Seeking Alpha - Wed Nov 19, 9:14AM CST
MACK: 8.73 (-0.21)
Merrimack Pharmaceuticals Receives FDA Fast Track Designation for MM-398 in Post-Gemcitabine Metastatic Pancreatic Cancer
GlobeNewswire - Wed Nov 19, 7:07AM CST
Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) announced today that the U.S. Food and Drug Administration (FDA) has granted MM-398 (nanoliposomal irinotecan injection), also known as ''nal-IRI,'' Fast Track designation for the treatment of patients with metastatic adenocarcinoma of the pancreas who have been previously treated with gemcitabine-based therapy. Fast Track is designed by the FDA to facilitate and expedite the development and review of drugs that treat serious conditions and fill an unmet medical need.
MACK: 8.73 (-0.21), BAX: 72.45 (-0.13)
Global Cervical Cancer Therapeutic Pipeline Review, H2 2014 - 35 Companies & 71 Drug Profiles
M2 - Wed Nov 19, 4:19AM CST
Research and Markets (http://www.researchandmarkets.com/research/4p52hn/cervical_cancer) has announced the addition of the "Cervical Cancer - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cervical Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cervical Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - F. Hoffmann-La Roche Ltd. - Sanofi - GlaxoSmithKline plc - Nektar Therapeutics - Inovio Pharmaceuticals, Inc. - Daiichi Sankyo Company, Limited - Amorfix Life Sciences Ltd. - MediGene AG - Nanotherapeutics, Inc. - Arbor Vita Corporation - Novartis AG - Chong Kun Dang Pharmaceutical Corp. - Taiho Pharmaceutical Co., Ltd. - Zeria Pharmaceutical Co Ltd - Genmab A/S - Advaxis, Inc. - 3SBio Inc. - Transgene SA - Antigen Express, Inc. - Shantha Biotechnics Limited - Bionor Pharma ASA - Azaya Therapeutics Incorporated - Merrimack Pharmaceuticals, Inc. - Genexine, Inc. - Genticel - Sirnaomics, Inc. - EyeGene, Inc. - Vaccibody AS - Wellstat Biologics Corporation - ISA Pharmaceuticals B.V. For more information visit http://www.researchandmarkets.com/research/4p...cal_cancer
MACK: 8.73 (-0.21), INO: 9.43 (-0.43), ADXS: 2.90 (-0.01), GSK: 46.24 (-0.04), NKTR: 13.93 (-0.16), NVS: 95.69 (+0.11)
Cramer's Lightning Round - Mobileye Will Have A Good Quarter (11/17/14)
SA Editor Miriam Metzinger - Seeking Alpha - Tue Nov 18, 5:40AM CST
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Monday November 17. Bullish Calls: Mobileye (NYSE: MBLY ) : "It has come down. I do feel it could have a good quarter. It has had a good run, there...
MACK: 8.73 (-0.21), DSX: 7.75 (-0.05), BIIB: 302.65 (-2.91), GE: 26.81 (-0.20), ALNY: 89.95 (unch), JCP: 7.20 (-0.12), MBLY: 46.51 (-0.82)
'Mad Money' Lightning Round: I'm Buy, Buy, Buying Biogen
at The Street - Tue Nov 18, 5:00AM CST
Cramer's not recommending J.C. Penney, likes Alnylam Pharmaceuticals and thinks GE is getting better.
MACK: 8.73 (-0.21), DSX: 7.75 (-0.05), BIIB: 302.65 (-2.91), GE: 26.81 (-0.20), ALNY: 89.95 (unch), JCP: 7.20 (-0.12), MBLY: 46.51 (-0.82)
Jim Cramer's 'Mad Money' Recap: When Bad News Is Really Good News for Us
at The Street - Mon Nov 17, 7:09PM CST
Cramer says this morning's losses and afternoon's gains prove that not all markets need to trade in tandem.
CST: 43.28 (+0.86), BIIB: 302.65 (-2.91), GE: 26.81 (-0.20), NKE: 96.79 (+0.32), HAL: 48.43 (-0.11), TSN: 43.09 (+0.44), GSAT: 2.65 (+0.10), LULU: 45.32 (+0.52), AGN: 212.57 (-0.80), MACK: 8.73 (-0.21), WHR: 179.50 (+2.28), UA: 70.23 (+0.86), DSX: 7.75 (-0.05), ALNY: 89.95 (unch), MPC: 94.05 (+0.17), JCP: 7.20 (-0.12), SHW: 240.10 (-1.22), MBLY: 46.51 (-0.82), REGN: 415.62 (+2.40), BHI: 63.41 (-0.14)
Photo Release -- Merrimack Pharmaceuticals Announces the Addition of Vivian S. Lee, Dean of University of Utah School of Medicine, to Its Board of Directors
GlobeNewswire - Mon Nov 17, 7:42AM CST
Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced the election of Vivian S. Lee, Ph.D., M.D., M.B.A. to its Board of Directors. Lee currently serves as the Senior Vice President for Health Sciences at the University of Utah, Dean of the University's School of Medicine, and CEO of University of Utah Health Care, overseeing 15,000 employees.
MACK: 8.73 (-0.21)
Insider Trading Alert - TASR, SAVE And MACK Traded By Insiders
at The Street - Fri Nov 14, 11:49AM CST
Stocks with insider trader activity include TASR, SAVE and MACK
MACK: 8.73 (-0.21), SAVE: 75.92 (-0.41), TASR: 20.13 (unch)
Biothera Names Carey Anderson VP of Regulatory Affairs
Business Wire - Thu Nov 13, 8:30AM CST
Carey Anderson has joined Biothera as Vice President of Regulatory Affairs for its Pharmaceutical business.
MACK: 8.72 (-0.22), AMGN: 162.62 (+0.38)
Merrimack Pharmaceuticals to Present Advances on Targeted Cancer Molecules at the 2014 AACR-NCI-EORTC International Conference
GlobeNewswire - Thu Nov 13, 7:02AM CST
Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that it will present research on three of its therapeutic candidates at the 2014 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, November 18-21, 2014 in Barcelona, Spain. Data will be shared in four poster sessions. Presentations will include results from a clinical study using ferumoxytol as a magnetic resonance imaging agent and its ability to predict tumor response to MM-398, preclinical and clinical research on MM-151 and an initial preclinical study of MM-131, a novel bispecific antibody targeting the c-Met tumor signaling pathway.
MACK: 8.72 (-0.22)
Merrimack Pharma ups revenues 306% in Q3
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 10:09AM CST
MACK: 8.72 (-0.22)
Merrimack Pharmaceuticals' (MACK) CEO Bob Mulroy on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Nov 10, 9:29PM CST
MACK: 8.72 (-0.22)
Merrimack posts 3Q loss
Automated Insights - Mon Nov 10, 5:57PM CST
CAMBRIDGE, Mass. (AP) _ Merrimack Pharmaceuticals Inc. (MACK) on Monday reported a loss of $27.9 million, or 27 cents per share, in its third quarter.
MACK: 8.72 (-0.22)
Merrimack Pharmaceuticals Reports Third Quarter 2014 Financial Results
GlobeNewswire - Mon Nov 10, 3:11PM CST
Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK), a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of cancer, today announced its third quarter 2014 financial results. Merrimack will host a live conference call and webcast today, Monday, November 10 at 4:30 p.m., Eastern Time, to provide an update on Merrimack's progress as well as a summary of these results.
MACK: 8.72 (-0.22)
Merrimack Pharmaceuticals misses by $0.15, beats on revenue
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 3:09PM CST
MACK: 8.72 (-0.22)
What To Watch For: November 10-14
TipRanks - Seeking Alpha - Mon Nov 10, 10:36AM CST
Quarterly report releases are winding down as we reach mid-November. Stay ahead of Wall Street with this week’s top stories: Monday, November 10 Sotheby’s (NYSE: BID ): a worldwide broker of fine art and real estate ...
BID: 39.48 (-0.32), DHI: 24.77 (+0.14), MGNX: 24.18 (-0.40), KSS: 57.37 (+0.24), HK: 2.90 (+0.02), SEAS: 17.09 (+0.03), DDD: 36.01 (+0.64), SBH: 30.34 (+0.53), WMT: 85.16 (+1.37), M: 61.83 (+0.38), HP: 78.05 (+0.15), NTAP: 41.79 (-0.10), ENR: 123.85 (-0.67), MACK: 8.72 (-0.22), W: 22.20 (+0.12), FOSL: 107.70 (-0.32), AMAT: 22.62 (-0.06), JCP: 7.20 (-0.12), JWN: 73.66 (+0.14), PE: 16.74 (+0.23), DF: 16.93 (+0.01), VIAB: 73.06 (-0.69), CSCO: 26.50 (-0.09), ATW: 37.04 (+0.02)
Will Inovio (INO) Disappoint Expectations for Q3 Earnings? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 3:35PM CST
Inovio (INO), which is scheduled to report third-quarter results on Nov 10, had delivered a negative earnings surprise of 11.76% in the last quarter.
MACK: 8.73 (-0.21), MNK: 85.19 (-3.61), INO: 9.44 (-0.42)
Can Merrimack (MACK) Keep the Earnings Streak Alive in Q3? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 3:30PM CST
Merrimack Pharmaceuticals, Inc. (MACK) has a Zacks Rank #2 and an Earnings ESP of +437.50%.
MACK: 8.73 (-0.21), MNK: 85.19 (-3.61), BAX: 72.45 (-0.13), LLY: 66.97 (-0.81)
Will Intercept Pharmaceuticals' (ICPT) Q3 Loss Narrow? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 3:02PM CST
Intercept Pharmaceuticals, Inc (ICPT) is slated to report its third-quarter 2014 results on Nov 7.
MACK: 8.73 (-0.21), MNK: 85.19 (-3.61), DNDN: 0.13 (-0.02), ICPT: 155.65 (-6.85)
MACK Recent Posts: http://investorshangout.com/Merrimack-Pharmac...ACK-90045/
MACK Merrimack Pharmaceuticals Inc Recent Headline News
Insider Trading Alert - MACK, GWRE And CCOI Traded By Insiders
at The Street - 2 hrs 21 mins ago
Stocks with insider trader activity include MACK, GWRE and CCOI
MACK: 8.73 (-0.21), GWRE: 49.41 (-0.67), CCOI: 34.83 (-0.32)
Merrimack cancer drug candidate Fast Track'd
Seeking Alpha - at Seeking Alpha - Wed Nov 19, 9:14AM CST
MACK: 8.73 (-0.21)
Merrimack Pharmaceuticals Receives FDA Fast Track Designation for MM-398 in Post-Gemcitabine Metastatic Pancreatic Cancer
GlobeNewswire - Wed Nov 19, 7:07AM CST
Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) announced today that the U.S. Food and Drug Administration (FDA) has granted MM-398 (nanoliposomal irinotecan injection), also known as ''nal-IRI,'' Fast Track designation for the treatment of patients with metastatic adenocarcinoma of the pancreas who have been previously treated with gemcitabine-based therapy. Fast Track is designed by the FDA to facilitate and expedite the development and review of drugs that treat serious conditions and fill an unmet medical need.
MACK: 8.73 (-0.21), BAX: 72.45 (-0.13)
Global Cervical Cancer Therapeutic Pipeline Review, H2 2014 - 35 Companies & 71 Drug Profiles
M2 - Wed Nov 19, 4:19AM CST
Research and Markets (http://www.researchandmarkets.com/research/4p52hn/cervical_cancer) has announced the addition of the "Cervical Cancer - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cervical Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cervical Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - F. Hoffmann-La Roche Ltd. - Sanofi - GlaxoSmithKline plc - Nektar Therapeutics - Inovio Pharmaceuticals, Inc. - Daiichi Sankyo Company, Limited - Amorfix Life Sciences Ltd. - MediGene AG - Nanotherapeutics, Inc. - Arbor Vita Corporation - Novartis AG - Chong Kun Dang Pharmaceutical Corp. - Taiho Pharmaceutical Co., Ltd. - Zeria Pharmaceutical Co Ltd - Genmab A/S - Advaxis, Inc. - 3SBio Inc. - Transgene SA - Antigen Express, Inc. - Shantha Biotechnics Limited - Bionor Pharma ASA - Azaya Therapeutics Incorporated - Merrimack Pharmaceuticals, Inc. - Genexine, Inc. - Genticel - Sirnaomics, Inc. - EyeGene, Inc. - Vaccibody AS - Wellstat Biologics Corporation - ISA Pharmaceuticals B.V. For more information visit http://www.researchandmarkets.com/research/4p...cal_cancer
MACK: 8.73 (-0.21), INO: 9.43 (-0.43), ADXS: 2.90 (-0.01), GSK: 46.24 (-0.04), NKTR: 13.93 (-0.16), NVS: 95.69 (+0.11)
Cramer's Lightning Round - Mobileye Will Have A Good Quarter (11/17/14)
SA Editor Miriam Metzinger - Seeking Alpha - Tue Nov 18, 5:40AM CST
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Monday November 17. Bullish Calls: Mobileye (NYSE: MBLY ) : "It has come down. I do feel it could have a good quarter. It has had a good run, there...
MACK: 8.73 (-0.21), DSX: 7.75 (-0.05), BIIB: 302.65 (-2.91), GE: 26.81 (-0.20), ALNY: 89.95 (unch), JCP: 7.20 (-0.12), MBLY: 46.51 (-0.82)
'Mad Money' Lightning Round: I'm Buy, Buy, Buying Biogen
at The Street - Tue Nov 18, 5:00AM CST
Cramer's not recommending J.C. Penney, likes Alnylam Pharmaceuticals and thinks GE is getting better.
MACK: 8.73 (-0.21), DSX: 7.75 (-0.05), BIIB: 302.65 (-2.91), GE: 26.81 (-0.20), ALNY: 89.95 (unch), JCP: 7.20 (-0.12), MBLY: 46.51 (-0.82)
Jim Cramer's 'Mad Money' Recap: When Bad News Is Really Good News for Us
at The Street - Mon Nov 17, 7:09PM CST
Cramer says this morning's losses and afternoon's gains prove that not all markets need to trade in tandem.
CST: 43.28 (+0.86), BIIB: 302.65 (-2.91), GE: 26.81 (-0.20), NKE: 96.79 (+0.32), HAL: 48.43 (-0.11), TSN: 43.09 (+0.44), GSAT: 2.65 (+0.10), LULU: 45.32 (+0.52), AGN: 212.57 (-0.80), MACK: 8.73 (-0.21), WHR: 179.50 (+2.28), UA: 70.23 (+0.86), DSX: 7.75 (-0.05), ALNY: 89.95 (unch), MPC: 94.05 (+0.17), JCP: 7.20 (-0.12), SHW: 240.10 (-1.22), MBLY: 46.51 (-0.82), REGN: 415.62 (+2.40), BHI: 63.41 (-0.14)
Photo Release -- Merrimack Pharmaceuticals Announces the Addition of Vivian S. Lee, Dean of University of Utah School of Medicine, to Its Board of Directors
GlobeNewswire - Mon Nov 17, 7:42AM CST
Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced the election of Vivian S. Lee, Ph.D., M.D., M.B.A. to its Board of Directors. Lee currently serves as the Senior Vice President for Health Sciences at the University of Utah, Dean of the University's School of Medicine, and CEO of University of Utah Health Care, overseeing 15,000 employees.
MACK: 8.73 (-0.21)
Insider Trading Alert - TASR, SAVE And MACK Traded By Insiders
at The Street - Fri Nov 14, 11:49AM CST
Stocks with insider trader activity include TASR, SAVE and MACK
MACK: 8.73 (-0.21), SAVE: 75.92 (-0.41), TASR: 20.13 (unch)
Biothera Names Carey Anderson VP of Regulatory Affairs
Business Wire - Thu Nov 13, 8:30AM CST
Carey Anderson has joined Biothera as Vice President of Regulatory Affairs for its Pharmaceutical business.
MACK: 8.72 (-0.22), AMGN: 162.62 (+0.38)
Merrimack Pharmaceuticals to Present Advances on Targeted Cancer Molecules at the 2014 AACR-NCI-EORTC International Conference
GlobeNewswire - Thu Nov 13, 7:02AM CST
Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that it will present research on three of its therapeutic candidates at the 2014 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, November 18-21, 2014 in Barcelona, Spain. Data will be shared in four poster sessions. Presentations will include results from a clinical study using ferumoxytol as a magnetic resonance imaging agent and its ability to predict tumor response to MM-398, preclinical and clinical research on MM-151 and an initial preclinical study of MM-131, a novel bispecific antibody targeting the c-Met tumor signaling pathway.
MACK: 8.72 (-0.22)
Merrimack Pharma ups revenues 306% in Q3
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 10:09AM CST
MACK: 8.72 (-0.22)
Merrimack Pharmaceuticals' (MACK) CEO Bob Mulroy on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Nov 10, 9:29PM CST
MACK: 8.72 (-0.22)
Merrimack posts 3Q loss
Automated Insights - Mon Nov 10, 5:57PM CST
CAMBRIDGE, Mass. (AP) _ Merrimack Pharmaceuticals Inc. (MACK) on Monday reported a loss of $27.9 million, or 27 cents per share, in its third quarter.
MACK: 8.72 (-0.22)
Merrimack Pharmaceuticals Reports Third Quarter 2014 Financial Results
GlobeNewswire - Mon Nov 10, 3:11PM CST
Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK), a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of cancer, today announced its third quarter 2014 financial results. Merrimack will host a live conference call and webcast today, Monday, November 10 at 4:30 p.m., Eastern Time, to provide an update on Merrimack's progress as well as a summary of these results.
MACK: 8.72 (-0.22)
Merrimack Pharmaceuticals misses by $0.15, beats on revenue
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 3:09PM CST
MACK: 8.72 (-0.22)
What To Watch For: November 10-14
TipRanks - Seeking Alpha - Mon Nov 10, 10:36AM CST
Quarterly report releases are winding down as we reach mid-November. Stay ahead of Wall Street with this week’s top stories: Monday, November 10 Sotheby’s (NYSE: BID ): a worldwide broker of fine art and real estate ...
BID: 39.48 (-0.32), DHI: 24.77 (+0.14), MGNX: 24.18 (-0.40), KSS: 57.37 (+0.24), HK: 2.90 (+0.02), SEAS: 17.09 (+0.03), DDD: 36.01 (+0.64), SBH: 30.34 (+0.53), WMT: 85.16 (+1.37), M: 61.83 (+0.38), HP: 78.05 (+0.15), NTAP: 41.79 (-0.10), ENR: 123.85 (-0.67), MACK: 8.72 (-0.22), W: 22.20 (+0.12), FOSL: 107.70 (-0.32), AMAT: 22.62 (-0.06), JCP: 7.20 (-0.12), JWN: 73.66 (+0.14), PE: 16.74 (+0.23), DF: 16.93 (+0.01), VIAB: 73.06 (-0.69), CSCO: 26.50 (-0.09), ATW: 37.04 (+0.02)
Will Inovio (INO) Disappoint Expectations for Q3 Earnings? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 3:35PM CST
Inovio (INO), which is scheduled to report third-quarter results on Nov 10, had delivered a negative earnings surprise of 11.76% in the last quarter.
MACK: 8.73 (-0.21), MNK: 85.19 (-3.61), INO: 9.44 (-0.42)
Can Merrimack (MACK) Keep the Earnings Streak Alive in Q3? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 3:30PM CST
Merrimack Pharmaceuticals, Inc. (MACK) has a Zacks Rank #2 and an Earnings ESP of +437.50%.
MACK: 8.73 (-0.21), MNK: 85.19 (-3.61), BAX: 72.45 (-0.13), LLY: 66.97 (-0.81)
Will Intercept Pharmaceuticals' (ICPT) Q3 Loss Narrow? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 3:02PM CST
Intercept Pharmaceuticals, Inc (ICPT) is slated to report its third-quarter 2014 results on Nov 7.
MACK: 8.73 (-0.21), MNK: 85.19 (-3.61), DNDN: 0.13 (-0.02), ICPT: 155.65 (-6.85)
